Design of a Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Lanreotide Depot 120 mg in Patients With Well Differentiated, Advanced Lung, or Thymus Neuroendocrine Tumors (NETs)

Reidy-Lagunes Diane; Wolin Edward M.; Pitman-Lowenthal Susan; Cox David; Kulke Matthew H.

首页> 外文期刊>Pancreas >Design of a Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Lanreotide Depot 120 mg in Patients With Well Differentiated, Advanced Lung, or Thymus Neuroendocrine Tumors (NETs)

【24h】

Design of a Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Lanreotide Depot 120 mg in Patients With Well Differentiated, Advanced Lung, or Thymus Neuroendocrine Tumors (NETs)

机译：设计一项2期，前瞻性，随机，双盲，安慰剂对照研究，评估兰瑞肽仓库120 mg在分化良好，晚期肺或胸腺神经内分泌肿瘤（NETs）患者中的疗效和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pancreas》 |2016年第3期|共2页
作者
Reidy-Lagunes Diane; Wolin Edward M.; Pitman-Lowenthal Susan; Cox David; Kulke Matthew H.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献

1. Design of a Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Lanreotide Depot 120 mg in Patients With Well Differentiated, Advanced Lung, or Thymus Neuroendocrine Tumors (NETs) [J] . Reidy-Lagunes Diane, Wolin Edward M., Pitman-Lowenthal Susan, Pancreas . 2016,第3期

机译：设计一项2期，前瞻性，随机，双盲，安慰剂对照研究，评估兰瑞肽仓库120 mg在分化良好，晚期肺或胸腺神经内分泌肿瘤（NETs）患者中的疗效和安全性
2. Safety and Efficacy of Everolimus in Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: Findings of the Randomized, Placebo-Controlled, Double-blind, Multicenter, Phase 3 RADIANT-4 Study [J] . Yao James C., Fazio Nicola, Singh Simron, Pancreas . 2016,第3期

机译：依维莫司在肺癌或胃肠道（GI）晚期非功能性神经内分泌肿瘤（NET）中的安全性和有效性起源：随机，安慰剂对照，双盲，多中心，3期RADIANT-4研究的发现
3. Efficacy of Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Neuroendocrine Tumor Patients: Follow-up Analysis of the ELECT Prospective, Randomized, Double-blind and Open-label Phases [J] . Fisher George A. Jr., Wolin Edward M., Kunz Pamela L., Pancreas . 2017,第3期

机译：甘油酯仓库/自凝胶对症状综合征（CS）对症控制的疗效疗效肿瘤患者：选举前瞻性，随机，双盲和开放标签阶段的随访分析
4. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
5. Rationale and design of decision: a double-blind randomized placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer [O] . Marcia S Brose, Christopher M Nutting, Steven I Sherman, 2011

机译：决策的依据和设计：一项双盲随机安慰剂对照的III期临床试验评估索拉非尼在局部晚期或转移性放射性碘（RAI）-难治性分化型甲状腺癌患者中的疗效和安全性
6. Design of a phase 3, international multicenter, prospective, randomized, double-blind, placebo controlled study assessing the efficacy and safety of lanreotide depot 120 mg in patients with well-differentiated, advanced typical and atypical lung neuroendocrine tumors (NETs) [O] . Reidy-Lagunes Diane, Wolin Edward M., Lowenthal Susan Pitman, 2016

机译：设计一项三期国际多中心，前瞻性，随机，双盲，安慰剂对照研究，评估120mg兰瑞肽在高度分化，晚期典型和非典型肺神经内分泌肿瘤（NETs）患者中的疗效和安全性

Design of a Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Lanreotide Depot 120 mg in Patients With Well Differentiated, Advanced Lung, or Thymus Neuroendocrine Tumors (NETs)

著录项

相似文献

相关主题

期刊订阅